Our vision is to improve human health and extend human longevity by unlocking the potential of CNS therapeutics around the world.
Our mission is to accelerate the development and commercialization of innovative therapeutics for the central nervous system (CNS) by building the next-generation of universally accessible interventional engineering tools for functional neurosurgery.
Neurochase was founded by Professor Steven Gill to bring transformative targeted therapies to patients with neurological diseases using state of the art technology. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol and a Consultant Neurosurgeon at Southmead Hospital, Bristol. He is a widely published, world-leading expert in Functional Neurosurgery having pioneered the targeting of novel brain structures to improve the treatment of Parkinson’s disease and tremor. He also carried out the first clinical trial of infusing GDNF directly into the brain which demonstrated the potential to reverse Parkinson’s disease. He is a prolific inventor and has, over the past 20 years, developed technology and software to facilitate highly accurate and safe targeting of deep brain structures using surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering carboplatin directly to paediatric brainstem tumours using his novel implantable neurosurgical device.
CNS Drug Delivery
Drug-device combination therapies utilising convection-enhanced delivery (CED) are an emerging therapeutic strategy for the treatment of neurological disorders. When delivered via CED, biologics and chemotherapeutics can achieve homogeneous distribution within a targeted brain structure while avoiding systemic immunogenicity and off target side effects. We believe that CED has the potential to transform human health by unlocking treatments to previously untreatable neurological disorders. At Neurochase, our goal is to develop the worlds most comprehensive drug development process for CED therapeutics.
Deep Brain Stimulation (DBS) and Convection Enhanced Delivery (CED) are translating into the clinic at a pace that far exceeds the number of neurosurgeons adequately trained in these techniques. In order to give patients access to cutting edge therapeutic strategies, our goal is to create a global centre of excellence that will recruit world leading experts in functional neurosurgery while training the next generation of doctors.
Variations between neurosurgical techniques for CED and DBS create asymmetric results for patients while complicating clinical trials. At Neurochase, we believe technology is the only way to democratise access to best in class CNS therapeutics. Currently available hardware and software solutions for CED are unable to scale globally. We are reimagining functional neurosurgery from the ground up.